Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Feb 14, 2024 11:35am
206 Views
Post# 35879832

RE:Anson update FYI

RE:Anson update FYIPlease do a little research on Anson Funds. 

It is almost certain that they have never held a single share of ONC.

IMO:

They shorted the 5 million shares in the weeks leading up to the private placement. 

They did this with ONC's tacit understanding/approval/assistance. 

ONC then issued 5 million new shares to cover Anson's short position.

ONC wins, they raise six months cash. Anson wins, they cover at a major discount to their short selling price. The existiting shareholders lose bigtime (65% haircut over the next six months).

Exactly like the ATM only bigger and quicker. 

And yet, here we are six months later and people still believe that Anson is a major institional shareholder. How funny and sad. 

The reason ONC shows on Anson's "books" is due to the layers and layers of internal paper shuffling and expert pratice in playing the game by Anson so as to not show the short position. 


<< Previous
Bullboard Posts
Next >>